Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer
- Sponsor
- Fundacion Oncosur
- Study ID
- NCT06377722
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Renal Cell Carcinoma Metastatic
- Renal Cell Carcinoma Stage III
- Renal Cell Carcinoma Stage IV
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Cabozantinib — DRUGThis study tries to clarify whether Cabozantinib could be a safe and effective preoperative treatment in patients with advanced RCC who were candidates for removing a part or all of their kidney.
Study Details
Phase II, multicenter, national, uncontrolled, multicenter, uncontrolled, phase II clinical trial for the evaluation of cabozantinib treatment prior to cytoreductive nephrectomy in patients with advanced or metastatic renal cell cancer candidates for primary tumor cytoreductive nephrectomy (NC).
Key Dates
- Start date
- Nov 1, 2018
- Status verified
- Apr 2024
- Primary completion
- Aug 9, 2022
- Completion
- Aug 9, 2022
Study Design
- Enrollment
- 18 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment with cabozantinib prior to cytoreductive nephrectomyTo evaluate the efficacy of preoperative cabozantinib treatment as measured by the radiological response rate prior to NC in patients with advanced or metastatic renal cell cancer candidates for NC.
Primary Outcome Measure
Radiological response rate prior to cytoreductive nephrectomy [ Time Frame: At 12 weeks following the start of the treatment. ]